Vertex Pharmaceuticals (VRTX)
NASDAQHealth CareBiotechnologySnapshot 2026-07-08
$522.25-1.39%
Close 2026-07-07 · 1-day change
Reading VRTX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track VRTX free→NASDAQHealth CareBiotechnologySnapshot 2026-07-08
Reading VRTX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track VRTX free→QuarterlyIQ Insights · VRTX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On July 6, 2026, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference. Cautionary Notice Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 related to the Company, Parent and the Transactions that are…
Entry into a Material Definitive Agreement. Merger Agreement On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”). Subject to the terms of the Merger Agreement, Merger Sub will be merged with and in…
The filing is about the approval of a new stock and option plan, not a management change.
Results of Operations and Financial Condition. On May 4, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three months ended March 31, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchan…
Director — Suketu Upadhyay: Mr. Upadhyay is leaving the Board due to scheduling conflicts with his new role as CFO at Incyte Corporation.
Results of Operations and Financial Condition. On February 12, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and twelve months ended December 31, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of t…
Results of Operations and Financial Condition. On November 3, 2025, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the…
Executive Vice President and Chief Scientific Officer — David Altshuler: David Altshuler is retiring from his role, but the departure is planned and not immediate.
Results of Operations and Financial Condition. On August 4, 2025, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and six months ended June 30, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securit…
Other Events. The Board of Directors of Vertex Pharmaceuticals Incorporated (the “Company”) has authorized an additional program to repurchase up to $4.0 billion of the Company’s common stock (the “2025 Repurchase Program”). The 2025 Repurchase Program does not have an expiration date and can be discontinued at any time. Under the 2025 Repurchase Program, the Company may repurchase stock from time to time, subject to general business and market conditions and other investment opportunities, o…
Results of Operations and Financial Condition. On May 5, 2025, we issued a press release in which we reported our consolidated financial results for the three months ended March 31, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject…
Chief Operating Officer — Stuart A. Arbuckle: Stuart A. Arbuckle is retiring as Chief Operating Officer, and Charles F. Wagner, Jr. will take over the role.
Results of Operations and Financial Condition. On February 10, 2025, we issued a press release in which we reported our consolidated financial results for the three and twelve months ended December 31, 2024. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…
Results of Operations and Financial Condition. On November 4, 2024, we issued a press release in which we reported our consolidated financial results for the three and nine months ended September 30, 2024. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Entry into a Material Definitive Agreement. On August 15, 202 4, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Vertex"), and SNH Seaport LLC, a Delaware limited liability company, entered into amendments (the "Headquarters Lease Amendments") to Vertex's leases of 50 Northern Avenue, Boston, MA, dated May 5, 2011 (the "50 Northern Avenue Lease") and 11 Fan Pier Boulevard, Boston, MA, dated May 5, 2011 (together with the 50 Northern Avenue Lease, the "Headquarters Leases")…
Results of Operations and Financial Condition. On August 1, 2024, we issued a press release in which we reported our consolidated financial results for the three and six months ended June 30, 2024. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwis…
Other Events. As previously disclosed, on May 20, 2024, Vertex Pharmaceuticals Incorporated (“Vertex”) completed its acquisition of Alpine Immune Sciences, Inc. (“Alpine”) for approximately $5.0 billion in cash (the “Alpine Acquisition”). Vertex expects to account for the Alpine Acquisition as an asset acquisition. Based on this determination, Vertex expects to record a one-time, non-deductible, Acquired In-Process Research & Development (“AIPR&D”) expense of approximately $4.4 billion during…
Other Events. On May 20, 2024, Vertex Pharmaceuticals Incorporated (“ Vertex ”) completed its acquisition of Alpine Immune Sciences, Inc. (“ Alpine ”) for approximately $5.0 billion in equity value (the “ Alpine Acquisition ”). The accounting treatment for the Alpine Acquisition will be finalized during the second quarter of 2024. Information Regarding the Completion of the Tender Offer On April 10, 2024, Vertex, a Massachusetts corporation, Adams Merger Sub, Inc., a Delaware corporation and…
Results of Operations and Financial Condition. On May 6, 2024, we issued a press release in which we reported our consolidated financial results for the three months ended March 31, 2024. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject…
Other Events. On April 10, 2024, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Cautionary Notice Regarding Forward-Looking Statements This communication contains forward-looking statements related to Parent, the Company and the proposed acquisition of the Company by Parent (the “ Transaction ”) that are subject to risks, uncertainties…
Entry into a Material Definitive Agreement. Merger Agreement On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”). The Merger Agreement provides that, subject to the terms of the Merger Agreement, Me…
Results of Operations and Financial Condition. On February 5, 2024, we issued a press release in which we reported our consolidated financial results for the three and twelve months ended December 31, 2023. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Director — Nancy Thornberry: Nancy Thornberry was appointed as a new member of the board of directors.
Results of Operations and Financial Condition. On November 6, 2023, we issued a press release in which we reported our consolidated financial results for the three and nine months ended September 30, 2023. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Director — Michel Lagarde: Michel Lagarde was appointed as a new member of the board of directors.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.